We reached 10,000 followers on LinkedIn & we’re speechless! Well, almost 😉
They say a picture says more than a thousand words, so to celebrate, we shared 10 pictures that exemplify what Bacthera stands for and why our partners choose to work with us ➡️https://t.co/Dzf2Vx76LT
Ever wondered where our name comes from? 🤔
It's a reflection of our core mission in the realm of LBPs.
As we continue to explore & expand the possibilities within this field, our name continually reminds us of our commitment to contributing to innovative healthcare solutions.
See our colleague Gemma Henderson in the latest episode of #MicrobiomeShorts with Dr. Amine ZORGANI!
Catch a sneak peek of the episode to learn more about LBPs or dive into the full video ➡ https://t.co/YWWpq8uYqB
Are you joining the @IAmBiotech#BioInternationalConvention?
Our Sr. BD Manager, Henri de Vlam will be at the @SwissBiotech Pavilion, booth 2111, from June 3-6. Book a meeting with Henri via the One-on-One Partnering tool and let’s see how we can work together!
It's already been a year since we acquired the cGMP manufacturing site in León, Spain, from 4D Pharma. After twelve months of dedication and collaboration, the integration has met our goals and allowed us to increase our production volumes substantially. ✨
📣 Last chance to APPLY!
Is your APAC LBP company advancing preclinical programs toward clinical trials? We are looking for single-strain solutions or specific strains within defined consortia. 🔬Want to win a free PoC study from Bacthera? APPLY NOW!👉 https://t.co/Kux0sdBN9j
Our colleagues Tue Hodal (CTO) & Lorenz Rindisbacher (CQO) wrote an article for EPR, in which they provide a comprehensive overview of current challenges, regulatory landscapes, & emerging strategies that are shaping the future of LBPs ➡
https://t.co/xLiN1zyrkB
👉 Meet Noora Ottman, the Head of Drug Substance at #Bacthera, whose experience across five countries uniquely positions her at the forefront of microbiological innovation.
Head to our LinkedIn post to learn more about Noora's experience 👉 https://t.co/sijHwLKn4m
Join us at #SwissBiotechDay! Our Global Head of Project & Portfolio Management, Gemma Henderson, will be one of the panelists. Alongside colleagues from @pharmabiome, @ferring & @OMPHARMA, Gemma will discuss the microbiome field, one year after the first market launch.
⭐️Last week's networking and learning continued as Alain Heron, our Head of Business Development together with our Head of DS and Head of DP and scientists, attended the @MicrobiomeTimes' #MicrobesInWomensHealth conference.
✨ Last week, Felix Faupel, our CCO, discussed the acceleration of commercial manufacturing for LBPs at the @medicon_valley conference in Copenhagen. Joining him were industry experts like Denise Kelly from @SeventureP and colleagues from @ferring and VCLS.
❓ Have you applied for the upcoming Preclinical Showcase competition? You can win a free PoC study from Bacthera! 👏
The competition is open to all LBP companies based in the APAC region. 🌏
Apply and find out more👉 https://t.co/Kux0sdBN9j
@MicrobiomeCNCT@KisacoRes
Hajar's poster is all about designing a women's health patient-friendly LBP containing 𝘓. 𝘳𝘩𝘢𝘮𝘯𝘰𝘴𝘶𝘴".
⭐️Women's health will be the focal point next week in Copenhagen at the Microbes in Women's Health Conference, presented by @MicrobiomeTimes.
Come & meet us there!
Press release:
BACTHERA RECEIVES MANUFACTURING LICENSES IN SWITZERLAND AND DENMARK
Read the full release and statements from our CEO, the CEO of @Chr_Hansen and the President, Division Head Biologics, Cell and Gene of @LonzaGroup right here:
https://t.co/TV6VHPOwIW
ANNOUNCING: Bacthera joins the Pharmabiotic Research Institute. With the ambition to become the globally leading #LiveBiotherapeuticProduct (LBP) #CDMO for the microbiome industry, joining PRI is an important step to further build on Bacthera’s position as a key industry player.
Today is the International Day of #WomenInScience! On this day, we want to take a moment to thank all the women contributing to make #LiveBiotherapeuticProducts (#LBP) a reality and uncovering the therapeutic potential of #bacteria!
Announcing technical completion of our Drug Substance Manufacturing Site in Denmark. Lukas Schüpbach, CEO, states: “I am excited to offer our customers GMP services based on leading technologies & infrastructure and would like to thank the team for the great accomplishment."
Making #LiveBiotherapeuticProducts (LBP's) a reality is a passion we share with our customers. And in order to do so, a customer centric and partnering approach is core to the way we work. #microbiota#microbiome#CDMO